Carragelose offers protection against SARS-CoV-2

27 August 2020

The impressive effectiveness of Carragelose (carrageenan), a sulfated polymer from red seaweed, against the new SARS-CoV-2 virus is confirmed by more and more studies, says Vienna, Austria-based Marinomed Biotech.

Pre-clinical data from cell culture tests show that Carragelose causes a significant, dose-dependent reduction in the infection of cells. Several independent studies have now confirmed these results.

A study from Tennessee/USA together with Argentinean researchers shows that Carragelose can reduce the replication of the virus by more than 99.99% even at extremely low doses. A clinical study, also conducted in Argentina, shows that a nasal spray with Carragelose in combination with the drug ivermectin offers a very high level of protection when used as a preventive measure. 229 healthy hospital employees participated in the study.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK